Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today reported financial results for the fourth quarter and full year ended December 31, 2005. Net income for the fourth quarter of 2005 was $305 million or $0.45 per share, an increase of 9% and 10%, respectively, over the same period in 2004. For the full year of 2005, net income was $1,072 million or $1.59 per share. On a standard U.S. GAAP basis, after taking into account certain charges in 2004 relating principally to the acquisition of Sicor, 2005 net income and net income per share increased 223% and 218%, respectively, over 2004. Excluding such charges from 2004, 2005 net income and net income per share increased 11% and 12%, respectively, over the full year of 2004. Teva believes that excluding the 2004 items represents a better indicator of the underlying trends in the Company’s operations.
